Speaker Name: Prof. Nikolaus Marx, Professor of Medicine/Cardiology, Head of Department, Internal Medicine, University Hospital, Aachen, Germany.

Explore this expert session to:

• Understand the expanding role of SGLT2i in reducing CV events and HF hospitalization in patients with T2DM and high CV risk.
• Review landmark trial evidence supporting SGLT2i use across HFrEF, HFmrEF, and HFpEF, irrespective of diabetes status.
• Evaluate kidney-protective benefits of SGLT2i, including delayed CKD progression and reduced cardiorenal outcomes across broad eGFR ranges.
• Interpret evidence supporting early in-hospital initiation of SGLT2i during ADHF admissions.
• Apply current ESC and KDIGO recommendations for patient selection, initiation thresholds, and practical safety monitoring with SGLT2i therapy.